Published in Leukemia on February 27, 2013
Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood (2013) 6.50
Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med (2014) 6.12
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia (2013) 3.93
Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med (2014) 3.75
Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature (2014) 2.79
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood (2014) 2.54
Emerging patterns of somatic mutations in cancer. Nat Rev Genet (2013) 2.50
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood (2014) 2.44
Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet (2013) 2.14
Somatic SETBP1 mutations in myeloid malignancies. Nat Genet (2013) 2.12
The genetic basis of myelodysplasia and its clinical relevance. Blood (2013) 1.95
SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLoS Comput Biol (2014) 1.88
The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation. PLoS Genet (2014) 1.74
Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). Blood (2013) 1.71
Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol (2014) 1.58
Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nat Genet (2015) 1.57
Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo. Cancer Cell (2015) 1.47
Mutations in G protein β subunits promote transformation and kinase inhibitor resistance. Nat Med (2014) 1.46
Clonal architecture of secondary acute myeloid leukemia defined by single-cell sequencing. PLoS Genet (2014) 1.18
Haploinsufficiency of del(5q) genes, Egr1 and Apc, cooperate with Tp53 loss to induce acute myeloid leukemia in mice. Blood (2013) 1.10
Mutational spectrum of adult T-ALL. Oncotarget (2015) 1.09
Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia. Cell Stem Cell (2017) 1.05
Runx1 Deficiency Decreases Ribosome Biogenesis and Confers Stress Resistance to Hematopoietic Stem and Progenitor Cells. Cell Stem Cell (2015) 1.04
PRPF8 defects cause missplicing in myeloid malignancies. Leukemia (2014) 1.00
Origins of aberrant DNA methylation in acute myeloid leukemia. Leukemia (2013) 1.00
Clinical and genetic predictors of prognosis in myelodysplastic syndromes. Haematologica (2014) 0.92
U2AF1 mutations alter sequence specificity of pre-mRNA binding and splicing. Leukemia (2014) 0.91
Cohesin mutations in myeloid malignancies: underlying mechanisms. Exp Hematol Oncol (2014) 0.90
SRSF2 Is Essential for Hematopoiesis, and Its Myelodysplastic Syndrome-Related Mutations Dysregulate Alternative Pre-mRNA Splicing. Mol Cell Biol (2015) 0.89
Genetic characterization of acquired aplastic anemia by targeted sequencing. Haematologica (2014) 0.87
Targeted resequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progression. Leukemia (2015) 0.85
Recent advances in myelodysplastic syndromes: Molecular pathogenesis and its implications for targeted therapies. Cancer Sci (2015) 0.84
High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS). Leukemia (2015) 0.84
Acquired copy number alterations of miRNA genes in acute myeloid leukemia are uncommon. Blood (2013) 0.84
MDS prognostic scoring systems – past, present, and future. Best Pract Res Clin Haematol (2014) 0.83
CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse. Biol Blood Marrow Transplant (2015) 0.83
Complex molecular genetic abnormalities involving three or more genetic mutations are important prognostic factors for acute myeloid leukemia. Leukemia (2015) 0.82
Recent advances in understanding clonal haematopoiesis in aplastic anaemia. Br J Haematol (2017) 0.81
Cohesin mutations in human cancer. Biochim Biophys Acta (2016) 0.81
Significance of myelodysplastic syndrome-associated somatic variants in the evaluation of patients with pancytopenia and idiopathic cytopenias of undetermined significance. Mod Pathol (2016) 0.81
Germline ETV6 mutations and predisposition to hematological malignancies. Int J Hematol (2017) 0.80
Implications of molecular genetic diversity in myelodysplastic syndromes. Curr Opin Hematol (2016) 0.80
Genomic characterization of pediatric T-cell acute lymphoblastic leukemia reveals novel recurrent driver mutations. Oncotarget (2016) 0.79
Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT). Curr Hematol Malig Rep (2014) 0.79
Understanding the mutational evolution of clonal cytopenias and oligoblastic myelogenous leukemia ('myelodysplasia'). Leukemia (2013) 0.79
Retroviral insertional mutagenesis identifies the del(5q) genes, CXXC5, TIFAB and ETF1, as well as the Wnt pathway, as potential targets in del(5q) myeloid neoplasms. Haematologica (2016) 0.79
Genomic tools in acute myeloid leukemia: From the bench to the bedside. Cancer (2014) 0.79
Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome. Nat Commun (2017) 0.78
Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget (2016) 0.78
Splicing-factor alterations in cancers. RNA (2016) 0.78
Whole-exome sequencing in del(5q) myelodysplastic syndromes in transformation to acute myeloid leukemia. Leukemia (2013) 0.78
The challenging world of cytopenias: distinguishing myelodysplastic syndromes from other disorders of marrow failure. Oncologist (2014) 0.77
The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nat Rev Cancer (2016) 0.77
Reduced levels of Hspa9 attenuate Stat5 activation in mouse B cells. Exp Hematol (2014) 0.76
In-depth mutational analyses of colorectal neuroendocrine carcinomas with adenoma or adenocarcinoma components. Mod Pathol (2016) 0.76
Clonotyping for precision oncology. Drug Discov Today (2015) 0.75
Peripheral blood cell-free DNA is an alternative tumor DNA source reflecting disease status in myelodysplastic syndromes. Cancer Sci (2016) 0.75
Multiplex ligation-dependent probe amplification assay identifies additional copy number changes compared with R-band karyotype and provide more accuracy prognostic information in myelodysplastic syndromes. Oncotarget (2016) 0.75
Targeted sequencing informs the evaluation of normal karyotype cytopenic patients for low-grade myelodysplastic syndrome. Leukemia (2016) 0.75
Hematopoietic Cell Transplantation for Older Patients with MDS. Mediterr J Hematol Infect Dis (2014) 0.75
Tales from the Jazz ASH: highlights from the 2013 American Society of Haematology meeting. Ecancermedicalscience (2014) 0.75
Short telomere length and its correlation with gene mutations in myelodysplastic syndrome. J Hematol Oncol (2016) 0.75
Downregulated stromal antigen 2 expression in de novo acute myeloid leukemia patients. Exp Ther Med (2017) 0.75
Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome. PLoS One (2016) 0.75
Preleukemia: One name, many meanings. Leukemia (2016) 0.75
Knockdown of HSPA9 induces TP53-dependent apoptosis in human hematopoietic progenitor cells. PLoS One (2017) 0.75
Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy. Leukemia (2016) 0.75
Peripheral blood mononuclear cell proteome changes in patients with myelodysplastic syndrome. Biomed Res Int (2015) 0.75
Splicing factor gene mutations in hematologic malignancies. Blood (2016) 0.75
Novel therapeutic strategies in myelodysplastic syndromes: do molecular genetics help? Curr Opin Hematol (2016) 0.75
Definition of MYC genetic heteroclonality in diffuse large B-cell lymphoma with 8q24 rearrangement and its impact on protein expression. Mod Pathol (2016) 0.75
Prognostic value of SRSF2 mutations in patients with de novo myelodysplastic syndromes: A meta-analysis. PLoS One (2017) 0.75
The clonal origins of leukemic progression of myelodysplasia. Leukemia (2017) 0.75
Clonal evolution in myelodysplastic syndromes. Nat Commun (2017) 0.75
The Sequence Alignment/Map format and SAMtools. Bioinformatics (2009) 232.39
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature (2008) 38.13
Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 33.09
VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res (2012) 15.90
DNMT3A mutations in acute myeloid leukemia. N Engl J Med (2010) 14.07
Frequent pathway mutations of splicing machinery in myelodysplasia. Nature (2011) 11.44
Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med (2011) 9.90
The origin and evolution of mutations in acute myeloid leukemia. Cell (2012) 9.66
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med (2011) 7.89
The structure of the G protein heterotrimer Gi alpha 1 beta 1 gamma 2. Cell (1995) 7.66
The 2.0 A crystal structure of a heterotrimeric G protein. Nature (1996) 6.77
Clonal architecture of secondary acute myeloid leukemia. N Engl J Med (2012) 6.71
De novo mutations of SETBP1 cause Schinzel-Giedion syndrome. Nat Genet (2010) 5.72
SomaticSniper: identification of somatic point mutations in whole genome sequencing data. Bioinformatics (2011) 5.62
MuSiC: identifying mutational significance in cancer genomes. Genome Res (2012) 4.73
Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet (2011) 4.02
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet (2012) 3.43
Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol (2012) 2.92
Molecular basis for interactions of G protein betagamma subunits with effectors. Science (1998) 2.88
Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood (2012) 2.88
TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol (2011) 2.88
SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia (2011) 2.82
Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood (2012) 2.69
Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood (2012) 1.88
TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. Br J Haematol (2013) 1.87
Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis. PLoS One (2009) 1.53
The expanding spectrum of G protein diseases. N Engl J Med (1999) 1.41
Gbetagamma activates GSK3 to promote LRP6-mediated beta-catenin transcriptional activity. Sci Signal (2010) 1.01
Initial sequencing and analysis of the human genome. Nature (2001) 212.86
Complete genome sequence of Salmonella enterica serovar Typhimurium LT2. Nature (2001) 16.89
bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell (1993) 14.39
A physical map of the human genome. Nature (2001) 12.39
Non-chromosomal antibiotic resistance in bacteria. II. Molecular nature of R-factors isolated from Proteus mirabilis and Escherichia coli. J Mol Biol (1970) 11.86
SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med (2008) 11.31
Common virulence factors for bacterial pathogenicity in plants and animals. Science (1995) 11.22
Multiple molecular species of circular R-factor DNA isolated from Escherichia coli. Nature (1969) 9.02
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol (1998) 8.40
Generation and analysis of 280,000 human expressed sequence tags. Genome Res (1996) 8.27
High throughput fingerprint analysis of large-insert clones. Genome Res (1997) 6.91
The complete nucleotide sequence of the Xenopus laevis mitochondrial genome. J Biol Chem (1985) 5.89
Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. Ann Neurol (1999) 5.83
Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest (2000) 5.07
Sequence and analysis of chromosome 4 of the plant Arabidopsis thaliana. Nature (1999) 5.03
Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome. Cell (1998) 4.72
Longitudinal observations on a selected group of local health departments: a preliminary report. J Public Health Policy (1993) 4.50
Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia (2011) 4.28
Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell (1994) 4.26
The AZFc region of the Y chromosome features massive palindromes and uniform recurrent deletions in infertile men. Nat Genet (2001) 4.24
Targeted deletion of 5'HS2 of the murine beta-globin LCR reveals that it is not essential for proper regulation of the beta-globin locus. Genes Dev (1995) 4.11
Mice lacking neutrophil elastase reveal impaired host defense against gram negative bacterial sepsis. Nat Med (1998) 4.04
A survey of local public health departments and their directors. Am J Public Health (1977) 4.03
Barrel-stave model or toroidal model? A case study on melittin pores. Biophys J (2001) 3.80
Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res (1998) 3.79
Y-Chromosome evidence for a northward migration of modern humans into Eastern Asia during the last Ice Age. Am J Hum Genet (1999) 3.60
Undergraduate research. Genomics Education Partnership. Science (2008) 3.45
Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem (2001) 3.40
The physician-scientist: career issues and challenges at the year 2000. FASEB J (2000) 3.38
bcl-XL is the major bcl-x mRNA form expressed during murine development and its product localizes to mitochondria. Development (1994) 3.34
Mechanisms of light scattering from biological cells relevant to noninvasive optical-tissue diagnostics. Appl Opt (1998) 3.33
5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia. N Engl J Med (1982) 3.29
Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology (2001) 3.13
Cysteine3 of Src family protein tyrosine kinase determines palmitoylation and localization in caveolae. J Cell Biol (1994) 3.12
RNA processing errors in patients with beta-thalassemia. Proc Natl Acad Sci U S A (1982) 2.99
Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest (1997) 2.99
Impaired production and increased apoptosis of neutrophils in granulocyte colony-stimulating factor receptor-deficient mice. Immunity (1996) 2.95
Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc Natl Acad Sci U S A (1996) 2.93
Longitudinal pattern of regional brain volume change differentiates normal aging from MCI. Neurology (2009) 2.84
Long-range disruption of gene expression by a selectable marker cassette. Proc Natl Acad Sci U S A (1996) 2.83
Non-chromosomal antibiotic resistance in bacteria. 3. Isolation of the discrete transfer unit of the R-factor R1. Proc Natl Acad Sci U S A (1970) 2.76
Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences. Blood (1997) 2.72
DNA sequencing with dye-labeled terminators and T7 DNA polymerase: effect of dyes and dNTPs on incorporation of dye-terminators and probability analysis of termination fragments. Nucleic Acids Res (1992) 2.71
Novel fluorescent protein from Discosoma coral and its mutants possesses a unique far-red fluorescence. FEBS Lett (2000) 2.61
Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol (1998) 2.57
Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages. J Biol Chem (1993) 2.56
Measuring nicotine dependence among high-risk adolescent smokers. Addict Behav (1996) 2.54
Past adult lead exposure is linked to neurodegeneration measured by brain MRI. Neurology (2006) 2.52
Home delivery and neonatal mortality in North Carolina. JAMA (1980) 2.49
An encyclopedia of mouse genes. Nat Genet (1999) 2.48
Dipeptidyl peptidase I is required for the processing and activation of granzymes A and B in vivo. Proc Natl Acad Sci U S A (1999) 2.48
Chromosome 9p-linked families with frontotemporal dementia associated with motor neuron disease. Neurology (2009) 2.46
Role of cytochrome c and dATP/ATP hydrolysis in Apaf-1-mediated caspase-9 activation and apoptosis. EMBO J (1999) 2.45
Down-regulation of the novel gene melastatin correlates with potential for melanoma metastasis. Cancer Res (1998) 2.43
Recent changes in selected local health departments: implications for their capacity to guarantee basic medical services. Am J Prev Med (1988) 2.43
Development of leukemia in mice transgenic for the tax gene of human T-cell leukemia virus type I. Proc Natl Acad Sci U S A (1995) 2.43
Amoxicillin pharmacokinetics in pregnant women: modeling and simulations of dosage strategies. Clin Pharmacol Ther (2007) 2.38
Human epidermal growth factor receptor cDNA is homologous to a variety of RNAs overproduced in A431 carcinoma cells. Nature (1984) 2.36
Inducible transcription of five globin genes in K562 human leukemia cells. Proc Natl Acad Sci U S A (1983) 2.35
Enhancement of human eosinophil cytotoxicity and leukotriene synthesis by biosynthetic (recombinant) granulocyte-macrophage colony-stimulating factor. J Immunol (1986) 2.31
Optic-nerve degeneration in Alzheimer's disease. N Engl J Med (1986) 2.20
Mutation R120G in alphaB-crystallin, which is linked to a desmin-related myopathy, results in an irregular structure and defective chaperone-like function. Proc Natl Acad Sci U S A (1999) 2.18
Analysis of mice containing a targeted deletion of beta-globin locus control region 5' hypersensitive site 3. Mol Cell Biol (1996) 2.17
Beta O-39 thalassemia gene: a premature termination codon causes beta-mRNA deficiency without affecting cytoplasmic beta-mRNA stability. Blood (1984) 2.17
Developmental regulation of the Bcl-2 protein and susceptibility to cell death in B lymphocytes. EMBO J (1994) 2.16
Sequence and analysis of chromosome 5 of the plant Arabidopsis thaliana. Nature (2000) 2.16
An enhancer element lies 3' to the human A gamma globin gene. EMBO J (1987) 2.11
Frontotemporal dementia progresses to death faster than Alzheimer disease. Neurology (2005) 2.10
Clinical and molecular delineation of the 17q21.31 microdeletion syndrome. J Med Genet (2008) 2.09
Comparison of the Escherichia coli K-12 genome with sampled genomes of a Klebsiella pneumoniae and three salmonella enterica serovars, Typhimurium, Typhi and Paratyphi. Nucleic Acids Res (2000) 2.07
Estimation of the cortical functional connectivity with the multimodal integration of high-resolution EEG and fMRI data by directed transfer function. Neuroimage (2005) 2.06
Predictability of blood levels of gentamicin in man. J Infect Dis (1975) 2.06
Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res (2000) 2.05
Structure and localization of genes encoding aberrant and normal epidermal growth factor receptor RNAs from A431 human carcinoma cells. Mol Cell Biol (1985) 2.02
Statutory authorizations for the work of local health departments. Am J Public Health (1977) 2.01
Structural and functional analysis of the par region of the pSC 10 1 plasmid. Cell (1984) 1.98
harakiri, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins Bcl-2 and Bcl-X(L). EMBO J (1997) 1.97
Muscle-specific mutations accumulate with aging in critical human mtDNA control sites for replication. Proc Natl Acad Sci U S A (2001) 1.94
WD-40 repeat region regulates Apaf-1 self-association and procaspase-9 activation. J Biol Chem (1998) 1.93
Conservation of the primary structure, organization, and function of the human and mouse beta-globin locus-activating regions. Proc Natl Acad Sci U S A (1990) 1.89
Rapid identification of Enterobacteriaceae with microbial enzyme activity profiles. J Clin Microbiol (1981) 1.87
Estimation of in vivo human brain-to-skull conductivity ratio from simultaneous extra- and intra-cranial electrical potential recordings. Clin Neurophysiol (2005) 1.87
The program implications of administrative relationships between local health departments and state and local government. Am J Public Health (1981) 1.85
Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes. J Antimicrob Chemother (1981) 1.82
STAT-3 activation is required for normal G-CSF-dependent proliferation and granulocytic differentiation. Immunity (2001) 1.81
How do cytotoxic lymphocytes kill their targets? Curr Opin Immunol (1998) 1.80
Representation of cloned genomic sequences in two sequencing vectors: correlation of DNA sequence and subclone distribution. Nucleic Acids Res (1997) 1.78